

Marlex Pharmaceuticals issues voluntary nationwide recall of digoxin tablets USP, 0.125 mg and Digoxin tablets USP, 0.25 mg due to label mix-up

At Prime Therapeutics Management, we want to help you receive the best possible care. Visit **PrimeTherapeutics.com/DrugRecalls** to review the latest FDA drug recalls.

About this recall:

Marlex Pharmaceuticals is voluntarily recalling one lot of digoxin tablets USP, 0.125 mg, and one lot of digoxin tablets USP, 0.25 mg, to the consumer level due to label mix-up. Bottles of digoxin tablets, USP 0.125 mg, are incorrectly labeled and contain digoxin tablets USP, 0.25 mg tablets. Bottles of digoxin tablets USP, 0.25 mg are incorrectly labeled and contain digoxin tablets USP, 0.125 mg.

Digoxin is used for the treatment of mild to moderate heart failure. It increases heart muscle contraction in pediatric patients with heart failure. Digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. The product is packaged as 100 tablets in white HDPE bottles and labeled as indicated below with NDC, lot and expiration date. Marlex Pharmaceuticals, Inc has not received any reports of adverse events related to this recall.

What this means to you:

Consumers/distributors/retailers that have digoxin tablets USP, 0.125 mg, and digoxin tablets USP, 0.25 mg (lot number E3810 and lot number E3811), which are being recalled, should stop using/return to place of purchase. Marlex Pharmaceuticals is notifying its distributors and customers by emails and is arranging for return of all recalled products (lot number E3810 and lot number E3811).

Consumers with questions regarding this recall can contact Marlex Pharmaceuticals at **302.328.3355** or toll-free **888.582.1953** Monday–Friday, 8:30 a.m.–4:30 p.m. Eastern Standard Time (EST). Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking or using this drug product.

All brand names are property of their respective owners. FOR_176350 07/25 © 2025 Prime Therapeutics Management LLC, A Prime Therapeutics LLC Company